MannKind (MNKD) to Release Quarterly Earnings on Wednesday

MannKind (NASDAQ:MNKD) will be posting its quarterly earnings results before the market opens on Wednesday, August 7th. Analysts expect MannKind to post earnings of $0.01 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

MannKind (NASDAQ:MNKD) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.03 by $0.02. MannKind had a net margin of 3.78% and a negative return on equity of 3.35%. The business had revenue of $66.26 million during the quarter, compared to the consensus estimate of $60.55 million. During the same quarter in the previous year, the firm posted ($0.04) EPS. MannKind’s revenue was up 63.1% compared to the same quarter last year. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Trading Up 2.1 %

Shares of NASDAQ:MNKD traded up $0.11 during trading on Tuesday, reaching $5.34. 1,588,058 shares of the stock were exchanged, compared to its average volume of 2,702,951. The firm has a market cap of $1.45 billion, a PE ratio of 178.73 and a beta of 1.32. MannKind has a 12 month low of $3.17 and a 12 month high of $6.04. The stock has a 50-day moving average price of $5.21 and a 200-day moving average price of $4.54.

Insiders Place Their Bets

In related news, EVP David Thomson sold 23,537 shares of the business’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $4.66, for a total value of $109,682.42. Following the completion of the transaction, the executive vice president now owns 873,616 shares of the company’s stock, valued at $4,071,050.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 29,991 shares of company stock worth $142,093 in the last 90 days. Company insiders own 3.00% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $6.50 price objective on shares of MannKind in a report on Thursday, May 9th. Rodman & Renshaw began coverage on shares of MannKind in a research note on Thursday, June 13th. They issued a “buy” rating and a $8.00 price target on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, MannKind currently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.